What the research found

Researchers trained a machine-learning model on insulin pump dosing decisions from nearly 1,740 treatment courses to automate the selection of starting doses and daily adjustments in type 2 diabetes. The system performed better at recommending dose changes during ongoing treatment than at setting initial doses—a realistic finding, since fine-tuning therapy is often more predictable than first-line decisions.

In a prospective trial of 97 patients using model-guided dosing, median time spent in a target glucose range (3.9–10.0 mmol/L) reached 84.5%, with minimal hypoglycaemic episodes. The benefit held even for patients who had previously received insulin therapy. A key observation emerged: patients whose glucose stayed higher than expected in the first 24 hours tended to have worse control later, suggesting that early treatment response is a useful flag for identifying who might need closer monitoring or protocol adjustment.

Why it matters for you

If you're tracking insulin therapy as part of your protocol, this hints at a future where pump adjustments become more data-informed and less reliant on guesswork or frequent clinic visits. The model's ability to titrate basal and bolus doses daily could reduce the manual burden of managing insulin, though humans still decide whether to adopt the recommendations.

The finding about early glucose response as a predictive signal is worth noting: if your glucose isn't dropping as expected in the first day of a new insulin regimen, that's a legitimate reason to flag it for review rather than waiting weeks to reassess. This aligns with the MyKine approach of using continuous glucose data to make faster, smaller adjustments.

For most MyKine users (who are typically optimising performance, body composition, or metabolic health rather than managing type 2 diabetes), this is more of a proof-of-concept that algorithmic dosing is feasible. It may inform future tools for managing exogenous insulin or GLP-1 titration if those protocols become more common in your tracking.

Caveats

• Prospective arm was modest (97 patients) and part of a randomized trial; longer follow-up data not reported here
• Model trained on type 2 diabetes cohorts; applicability to type 1 or other metabolic contexts unclear
• Early glucose response signal is correlational, not causal—doesn't prove that measuring it earlier will change outcomes
• No comparison of clinical outcomes (complications, quality of life, hypoglycaemia burden) beyond glycaemic control metrics
• Generalization risk: model performance depends on how similar new patients are to the training population